Finance

Beta
Lists
HYPE3:BVMF
Hypera SA
R$21.35
+0.19%
(+0.040) 1D
Jun 5, 11:34:59 AM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for HYPE3...
Open
R$21.24
High
R$21.42
Low
R$21.07
Mkt. cap
15.09B
Avg. vol.
3.89M
Volume
510.70K
Dividend
4.09%
Quarterly dividend
R$0.22
Ex-dividend date
Feb 9, 2026
P/E ratio
8.15
52-wk high
R$27.25
52-wk low
R$19.97
EPS
R$2.62
Shares outstanding
704.01M
No. of employees
11K
Open
R$21.24
High
R$21.42
Low
R$21.07
Mkt. cap
15.09B
Avg. vol.
3.89M
Volume
510.70K
Dividend
4.09%
Quarterly dividend
R$0.22
Ex-dividend date
Feb 9, 2026
P/E ratio
8.15
52-wk high
R$27.25
52-wk low
R$19.97
EPS
R$2.62
Shares outstanding
704.01M
No. of employees
11K
News stories
From sources across the web
Profile
Hypera Pharma is a Brazilian multinational pharmaceutical company and is the largest Brazilian pharmaceutical company by market capitalization. Headquartered in São Paulo, its business include pharmaceuticals, consumer healthcare and cosmetics products, and biotechnology products. Wikipedia
About Hypera SA
CEO-
Employees10.6K
Founded2001
HeadquartersItaim Bibi, State of São Paulo, Brazil
SectorPharmaceutical industry
Websitehypera.com.br
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (BRL)
R$0.55 / R$0.48
+13.81%beat
Revenue / Est. (BRL)
2.02B / 1.98B
+2.07%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in BRL
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in BRL
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.15B
2.23B
2.24B
2.02B
Cost of goods sold
858.85M
865.21M
858.94M
807.22M
Cost of revenue
858.85M
865.21M
858.94M
807.22M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
663.84M
687.46M
728.46M
703.28M
Operating expense
649.05M
688.45M
728.74M
701.06M
Total operating expenses
1.51B
1.55B
1.59B
1.51B
Operating income
646.03M
673.59M
649.38M
509.50M
Other non operating income
-8.87M
-14.67M
-27.28M
-8.73M
EBT including unusual items
433.99M
448.11M
439.21M
276.14M
EBT excluding unusual items
436.68M
452.42M
438.30M
279.75M
Income tax expense
7.90M
-5.77M
-10.46M
-69.54M
Effective tax rate
1.82%
-1.29%
-2.38%
-25.18%
Other operating expenses
-14.78M
987.00K
283.00K
-2.21M
Net income
426.69M
457.64M
450.99M
347.38M
Net profit margin
19.81%
20.55%
20.16%
17.22%
Earnings per share
0.68
0.72
0.71
0.55
Interest and investment income
49.38M
69.23M
68.87M
64.66M
Interest expense
-253.18M
-283.65M
-268.84M
-282.34M
Net interest expenses
-203.79M
-214.42M
-199.97M
-217.68M
Depreciation and amortization charges
-
-
-
-
EBITDA
694.71M
728.99M
702.34M
567.09M
Gain or loss from assets sale
-1.54M
-11.00K
-253.00K
-3.20M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer